Bioregenx, INC

BioRegenx, Inc. reports the resignation of two directors, Gary Hennerberg and Gary Kiss, effective immediately.

Robert Doran has resigned from his position as director of BioRegenx, Inc., effective January 31, 2025.

BioRegenx, Inc. has appointed Richard Janney to its board of directors and formed an audit committee, effective October 7, 2024.

BioRegenx Inc. has completed a reverse merger with Findit, Inc., restated its financials for 2022 and 2023, and provided unaudited pro forma combined financial information for the year ended December 31, 2023.

BioRegenx, Inc. announces the resignation of Sherri Adams as an officer and director, effective July 17, 2024, to pursue other business interests.

Jody M. Walker has resigned from the BioRegenx Board of Directors effective July 13, 2024, due to her retirement.

BioRegenx reports a net loss of $26,415 for Q1 2026 while highlighting substantial doubt regarding its ability to continue as a going concern due to defaults on $522,500 in debt.

BioRegenx reports a significant reduction in net loss for Q3 2025, despite a 22% drop in net sales and ongoing concerns about debt defaults and internal control weaknesses.

BioRegenx, Inc. reports a reduced net loss but faces significant revenue decline and ongoing going concern doubts, with key loans in default and material weaknesses in internal controls.

BioRegenx's Q1 2025 results show a decrease in net sales but a significant reduction in net loss due to decreased operating expenses.

BioRegenx's Q3 2024 report reveals a net loss of $4.65 million, a 39% increase compared to the same period last year, alongside restated financials and identified material weaknesses in internal controls.

BioRegenx, Inc. reports a significant increase in net losses for the second quarter of 2024, driven by decreased sales, increased returns, and higher operating expenses following a merger and product issues.

BioRegenx, Inc. filed its 2025 10-K, reporting a 21% decrease in net sales to $1.85 million and a significant reduction in net loss to $1.54 million, while facing ongoing going concern uncertainties.

BioRegenx, Inc. files an amended 10-K to correct a transcription error in the consolidated statement of deficit, while reporting a substantial increase in net loss for the fiscal year ended December 31, 2024.

BioRegenx, Inc. reports a substantial net loss of $23.05 million for the year ended December 31, 2024, driven by decreased sales, amortization and impairment expenses.

BioRegenx, Inc., formerly Findit, Inc., released its 2023 annual report, detailing a year of significant transformation including a merger and strategic acquisitions aimed at expanding its presence in the health and wellness market.